- Published at
- by manilatimes.net
mixed
mixed
News for Black Diamond Therapeutics, Inc. (BDTX)
- Published at
- by gurufocus.com
positivepositiveBB Biotech AG Expands Stake in Black Diamond Therapeutics Inc
BB Biotech AG, a prominent investment firm, recently executed a significant transaction by acquiring an additional 3,140,000 shares of Black Diamond Therapeutic- Published at
- by benzinga.com
mixedmixedWhy Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Agape ATP (NASDAQ:ATPC), Arcutis Biotherapeutics (NASDAQ:ARQT)
Shares of Sage Therapeutics, Inc. SAGE rose sharply in today's pre-market trading after the company confirmed the receipt of Biogen’s nonbinding $7.22/share a...- Published at
- by manilatimes.net
negativenegative- Published at
- by seekingalpha.com
negativenegativeBlack Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data (BDTX)
Preliminary results for BDTX-1535 in NSCLC patients are expected in early 2025. Read more about Black Diamond Therapeutics and the outlook for BDTX stock.- Published at
- by gurufocus.com
mixedmixedMarket Today: Super Micro's AI Surge and Google's Legal Battle
Market Overview Today's trading session exhibited a negative bias throughout the day. Major indices faced slight declines initially, which intensified in the af- Published at
- by investing.com
mixedmixedTD Cowen maintains Buy on Black Diamond Therapeutics By Investing.com
TD Cowen maintains Buy on Black Diamond Therapeutics- Published at
- by investing.com
neutralneutralBlack Diamond advances NSCLC treatment in Phase 2 trial By Investing.com
Black Diamond advances NSCLC treatment in Phase 2 trial- Published at
- by globenewswire.com
negativenegativeBlack Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq:...- Published at
- by investing.com
positivepositiveBlack Diamond stock holds Buy rating post-ESMO By Investing.com
Black Diamond stock holds Buy rating post-ESMO- Published at
- by globenewswire.com
mixedmixedBlack Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESM
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with...- Published at
- by seekingalpha.com
mixedmixedSmall-cap and mid-cap Health Care has room to rally - Roth MKM (NASDAQ:PSCH)
In a Technical Strategy report, Roth MKM analysts said that health care (PSCH), (XLV) will continue to ascend in their rankings.- Published at
- by seekingalpha.com
mixedmixedBlack Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM (NASDAQ:BDTX)
Black Diamond Therapeutics shows promising results in treating genetically defined cancers, including NSCLC and recurrent GBM. Learn more on BDTX stock here.- Published at
- by benzinga.com
positivepositiveBlack Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying - Bespoke Extracts (OTC:BSPK), Black Diamond Therapeutic (NASDAQ:BDTX)
The Dow Jones closed lower by around 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.- Published at
- by insidermonkey.com
mixedmixedHedge Fund and Insider Trading News: Bill Ackman, Crispin Odey, King Street Capital Management, Black Diamond Therapeutics, Inc. (BDTX), Nuix Ltd (NXLLF), and More
Brian Higgins has helped guide King Street Capital Management to pounce on some of the most high-profile distressed debt events of the past two decades, from Lehman Brothers Holdings to Revlon Inc.- Published at
- by rttnews.com
mixedmixed- Published at
- by pennystocks.com
mixedmixed- Published at
- by globenewswire.com
mixedmixedZevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
CELEBRATION, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare...- Published at
- by forbes.com
mixedmixedSteven Cohen Dives Into Chimerix
Guru adds to health care holdings with biotech focused on cancer, serious diseases- Published at
- by gurufocus.com
mixedmixedSteven Cohen Dives Into Chimerix
Steven Cohen Dives Into Chimerix, Stocks: CMRX,ALNY,DRNA,MRTX,GLPG,CRIS,AGLE,ATRA,BLU,BDTX, Steven Cohen, release date:Feb 24, 2021